Cathepsin S Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740520-cathepsin-s-ctss-or-ec-3-4-22-27-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Cathepsin S (CTSS or EC 3.4.22.27) Overview 6
Therapeutics Development 7
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Stage of Development 7
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Therapy Area 8
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Indication 9
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Cathepsin S (CTSS or EC 3.4.22.27) - Products under Development by Companies 12
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development 19
Amura Holdings Limited 19
F. Hoffmann-La Roche Ltd. 20
Fusion Antibodies Limited 21
Sanofi 22
Virobay Inc. 23
Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles 24
AM-3840 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AM-3876 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Fsn-0503h - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
RG-7625 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
RO-5461111 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SAR-114137 - Drug Profile 29

Access Report @ https://www.wiseguyreports.com/reports/740520-cathepsin-s-ctss-or-ec-3-4-22-27-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here